Burning Rock Biotech (BNR) | Financial Analysis & Statements
Burning Rock Biotech Ltd. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2025Income Metrics
Revenue
131.6M
Gross Profit
98.8M
75.10%
Operating Income
-16.1M
-12.26%
Net Income
-16.8M
-12.73%
EPS (Diluted)
$-1.60
Balance Sheet Metrics
Total Assets
812.2M
Total Liabilities
262.6M
Shareholders Equity
549.6M
Debt to Equity
0.48
Cash Flow Metrics
Free Cash Flow
16.4M
Revenue & Profitability Trend
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2024
Burning Rock Biotech Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 515.8M | 537.4M | 563.2M | 507.9M | 429.9M |
| Cost of Goods Sold | 153.4M | 174.2M | 183.2M | 143.7M | 116.0M |
| Gross Profit | 362.4M | 363.2M | 380.0M | 364.1M | 313.9M |
| Gross Margin % | 70.3% | 67.6% | 67.5% | 71.7% | 73.0% |
| Operating Expenses | |||||
| Research & Development | 232.3M | 347.0M | 421.9M | 367.9M | 263.9M |
| Selling, General & Administrative | 452.5M | 685.5M | 938.6M | 793.4M | 462.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 684.8M | 1.0B | 1.4B | 1.2B | 726.3M |
| Operating Income | -322.4M | -669.3M | -980.4M | -797.1M | -412.4M |
| Operating Margin % | -62.5% | -124.5% | -174.1% | -156.9% | -95.9% |
| Non-Operating Items | |||||
| Interest Income | 12.2M | 18.0M | 9.5M | 3.5M | 6.1M |
| Interest Expense | - | 0 | - | 1.5M | 667.0K |
| Other Non-Operating Income | -30.5M | 64.0K | 1.7M | -655.0K | -231.0K |
| Pre-tax Income | -340.7M | -651.3M | -969.2M | -795.8M | -407.2M |
| Income Tax | 5.9M | 2.4M | 2.0M | 899.0K | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -346.6M | -653.7M | -971.2M | -796.7M | -407.2M |
| Net Margin % | -67.2% | -121.6% | -172.4% | -156.9% | -94.7% |
| Key Metrics | |||||
| EBITDA | -235.0M | -517.5M | -857.9M | -745.6M | -373.9M |
| EPS (Basic) | $-33.70 | $-63.80 | $-93.50 | $-76.50 | $-68.80 |
| EPS (Diluted) | $-33.70 | $-63.80 | $-93.50 | $-76.50 | $-68.80 |
| Basic Shares Outstanding | 10293504 | 74443308 | 75336066 | 75552782 | 49761370 |
| Diluted Shares Outstanding | 10293504 | 74443308 | 75336066 | 75552782 | 49761370 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Burning Rock Biotech Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 519.8M | 615.1M | 905.5M | 1.4B | 1.9B |
| Short-term Investments | - | - | 0 | 63.8M | 362.1M |
| Accounts Receivable | 152.0M | 126.9M | 110.0M | 92.2M | 88.2M |
| Inventory | 53.8M | 69.0M | 130.3M | 123.2M | 68.0M |
| Other Current Assets | 395.0K | 2.8M | 10.3M | 867.0K | 1.1M |
| Total Current Assets | 776.6M | 884.1M | 1.3B | 1.8B | 2.5B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 105.4M | 64.7M | 100.0M | 129.1M | 32.5M |
| Goodwill | 421.0K | 964.0K | 2.0M | 5.2M | 3.5M |
| Intangible Assets | 421.0K | 964.0K | 2.0M | 5.2M | 3.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 7.9M | 5.1M | 20.9M | 45.1M | 23.0M |
| Total Non-Current Assets | 108.7M | 155.9M | 328.7M | 457.6M | 139.4M |
| Total Assets | 885.3M | 1.0B | 1.6B | 2.3B | 2.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 33.7M | 18.1M | 50.9M | 63.1M | 35.5M |
| Short-term Debt | 24.6M | 8.6M | 37.2M | 37.4M | 46.9M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 18.1M | 18.9M | 19.6M | 13.2M | 4.8M |
| Total Current Liabilities | 266.3M | 263.4M | 411.5M | 372.2M | 241.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 27.8M | 3.7M | 13.6M | 49.3M | 0 |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 10.4M | 4.5M | 4.1M | 11.8M | 228.0K |
| Total Non-Current Liabilities | 38.2M | 8.2M | 17.7M | 61.1M | 491.0K |
| Total Liabilities | 304.5M | 271.6M | 429.1M | 433.3M | 242.0M |
| Equity | |||||
| Common Stock | 145.0K | 137.0K | 138.0K | 137.0K | 137.0K |
| Retained Earnings | -4.2B | -3.9B | -3.2B | -2.2B | -1.4B |
| Treasury Stock | 63.3M | 65.9M | 58.9M | 0 | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 580.8M | 768.4M | 1.2B | 1.8B | 2.4B |
| Key Metrics | |||||
| Total Debt | 52.3M | 12.3M | 50.8M | 86.7M | 46.9M |
| Working Capital | 510.3M | 620.7M | 847.3M | 1.4B | 2.3B |
Balance Sheet Composition
Burning Rock Biotech Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -346.6M | -653.7M | -971.2M | -796.7M | -407.2M |
| Depreciation & Amortization | 52.2M | 133.4M | 124.1M | 47.8M | 33.3M |
| Stock-Based Compensation | 155.6M | 260.7M | 326.8M | 282.4M | 173.2M |
| Working Capital Changes | -47.1M | -45.3M | -78.7M | -71.8M | 74.6M |
| Operating Cash Flow | -159.6M | -269.6M | -562.1M | -502.7M | -126.1M |
| Investing Activities | |||||
| Capital Expenditures | -3.9M | -8.0M | -67.9M | -210.4M | -74.9M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | 0 | 0 | -63.9M | -348.4M |
| Investment Sales | 0 | 0 | 65.6M | 358.5M | 318.0M |
| Investing Cash Flow | -3.9M | -8.0M | -7.3M | 84.2M | -105.3M |
| Financing Activities | |||||
| Share Repurchases | -72.0K | -7.0M | -71.8M | -4.3M | -3.5M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | 0 | 0 | 18.2M |
| Debt Repayment | 0 | 0 | -2.4M | -44.8M | -43.8M |
| Financing Cash Flow | -72.0K | -7.0M | -88.6M | -57.9M | 2.1B |
| Free Cash Flow | -98.2M | -265.2M | -527.3M | -691.3M | -153.1M |
| Net Change in Cash | -163.5M | -284.6M | -658.0M | -476.3M | 1.9B |
Cash Flow Trend
Burning Rock Biotech Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-0.61
Forward P/E
-35.60
Price to Book
2.76
Price to Sales
0.41
PEG Ratio
0.01
Profitability Ratios
Profit Margin
-10.26%
Operating Margin
-9.53%
Return on Equity
-9.92%
Return on Assets
-4.02%
Financial Health
Current Ratio
2.99
Debt to Equity
8.06
Beta
1.60
Per Share Data
EPS (TTM)
$-0.75
Book Value per Share
$7.49
Revenue per Share
$50.03
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BNR | 221.7M | -0.61 | 2.76 | -9.92% | -10.26% | 8.06 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Fonar | 118.6M | 16.35 | 0.70 | 6.01% | 7.13% | 24.44 |
| Biodesix | 107.5M | - | -34.62 | -383.09% | -39.85% | -30.44 |
| Oncocyte | 65.6M | -0.81 | 109.66 | 496.38% | 39.34% | 3.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.





